Business Context and Reporting Period
Company: Adherex Technologies Inc. (Note: Request metadata listed "Fennec Pharmaceuticals," but the filing text identifies the registrant as Adherex Technologies Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Stage: Development-stage biopharmaceutical company focused on cancer therapeutics.
Key Focus: The company is prioritizing the development of oral eniluracil (a DPD inhibitor) in combination with 5-FU and leucovorin. It is also supporting Phase III trials for STS (a chemoprotectant) and an investigator-led Phase I study for ADH-1.
Key Financial Metrics
| Metric (in thousands USD) | Q1 2010 | Q1 2009 | Balance Sheet (Mar 31, 2010) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(366) | $(2,246) | N/A |
| Operating Expenses | $366 | $1,952 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $348 |
| Working Capital | N/A | N/A | $47 |
| Accumulated Deficit | N/A | N/A | $(101,357) |
| Total Liabilities | N/A | N/A | $430 |
Note: All financial figures are in thousands of U.S. dollars unless otherwise noted.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased significantly from $1.952 million in Q1 2009 to $366,000 in Q1 2010. This 82% reduction is attributed to decreased clinical development activities and a reduction in employee headcount.
- Net Loss Improvement: Net loss narrowed from $2.246 million in Q1 2009 to $366,000 in Q1 2010, driven primarily by the reduction in operating costs.
- Liquidity Decline: Cash and cash equivalents decreased from $685,000 at December 31, 2009, to $348,000 at March 31, 2010. Working capital dropped from $412,000 to $47,000.
- Interest Income: Interest income was negligible in Q1 2010 compared to $46,000 in Q1 2009, reflecting lower cash balances.
Outlook, Risks, and Subsequent Events
- Subsequent Financing: On April 30, 2010 (post-period), the company completed the first closing of a non-brokered private placement, raising gross proceeds of CDN$7.2 million ($7.2 million CAD). The company intends to raise up to an additional CDN$1.8 million via private placement and up to CDN$12.75 million via a rights offering.
- Use of Proceeds: Funds are designated for conducting a Phase II Eniluracil study, satisfying corporate overhead, and paying financing expenses.
- Going Concern: The financial statements include a "Going Concern" note. The company has incurred significant losses and negative cash flows since inception. The statements do not reflect adjustments that would be necessary if the company were unable to continue operations, though the April 2010 financing mitigates immediate risk.
- Listing Status: The company's stock trades on the Toronto Stock Exchange (TSX) and over-the-counter in the U.S. (Pink Sheets). The TSX issued a delisting review on April 22, 2010, granting the company 120 days to regain compliance with listing standards.
- Risk Factors: Risks include the inability to effectively deploy new capital, failure of clinical trials, and the need for continued funding to sustain operations beyond the second quarter of 2010 (though the subsequent financing addresses the immediate need).
Investor Verification Checklist
- Capital Adequacy: Verify the status of the remaining closings of the private placement and the rights offering announced in April 2010 to ensure sufficient runway for the Phase II Eniluracil study.
- Listing Compliance: Monitor the company's progress in meeting TSX listing requirements within the 120-day window to avoid delisting.
- Clinical Progress: Confirm the timeline for the redesigned Phase II study of eniluracil, 5-FU, and leucovorin, which management expects to commence within nine months of the filing date.
- Share Dilution: Assess the impact of the 240 million+ units issued in the April 2010 financing and potential future issuances on existing shareholder equity.